karen
sim
md
phd
emili
blumberg
md
b
despit
quarter
centuri
experi
lung
transplant
mark
advanc
surgic
techniqu
immunosuppress
medic
prophylaxi
strategi
surviv
among
lung
transplant
recipi
lag
behind
solidorgan
transplant
sot
recipi
part
situat
may
attribut
infectionrel
complic
continu
major
sourc
morbid
mortal
patient
lung
allograft
uniqu
remain
constant
exposur
environ
potenti
respiratori
pathogen
natur
transplant
procedur
advers
affect
normal
host
defens
includ
impair
cough
mechan
mucociliari
clearanc
addit
contributor
includ
risk
crosscontamin
transplant
lung
nativ
lung
singlelungtranspl
patient
reduct
immun
system
function
high
immunosuppress
requir
lung
transplant
implement
care
strategi
pretranspl
screen
recipi
donor
pretransplant
posttransplant
vaccin
antimicrobi
prophylaxi
microbi
surveil
techniqu
incid
sever
infecti
complic
transplant
minim
review
overview
common
increasingli
challeng
infect
lung
transplant
provid
guidanc
current
prevent
treatment
strategi
prevent
infecti
complic
sot
paramount
care
pretranspl
evalu
risk
infecti
diseas
conduct
potenti
recipi
comprehens
recommend
evalu
sot
candid
aspect
transplantrel
infecti
diseas
recent
summar
guidelin
american
societi
transplant
ast
infecti
diseas
commun
practic
consult
specialist
infecti
diseas
transplant
alway
consid
part
pretransplant
evalu
care
medic
social
travel
histori
perform
ascertain
potenti
exposur
problem
pathogen
endem
mycos
parasit
infect
appropri
risk
stratif
occur
includ
consider
specif
posttransplant
prophylaxi
vaccin
histori
review
care
attent
paid
complet
childhood
vaccin
seri
ie
measlesmumpsrubella
histori
infect
pathogen
varicella
chicken
pox
mainten
adult
vaccin
schedul
mani
case
patient
primari
diseas
process
may
render
function
immunosuppress
initi
miss
delay
vaccin
seri
begin
earli
transplant
evalu
possibl
especi
live
attenu
vaccin
varicella
vaccin
varivax
merck
west
point
pa
usa
current
contraind
sot
vaccin
must
delay
transplant
center
defer
administr
month
transplant
baselin
immunosuppress
level
achiev
vaccin
statu
household
contact
famili
member
also
assess
optim
protect
transplant
recipi
date
transplant
possibl
current
recommend
routin
adult
vaccin
summar
tabl
transplant
candid
screen
presenc
antibodi
cmv
varicellazost
viru
epsteinbarr
viru
hepat
b
viru
hepat
c
viru
human
immunodefici
viru
assess
suitabl
transplant
appropri
risk
stratif
prophylaxi
vaccin
applic
monitor
transplant
screen
tuberculosi
tb
perform
transplant
candid
either
purifiedprotein
deriv
mantoux
skin
test
interferon
g
releas
assay
quantiferon
tb
gold
cellesti
valencia
ca
usa
test
tuberculintestposit
patient
evalu
activ
tb
latent
tb
treatment
prefer
month
isoniazid
recommend
transplant
candid
receiv
previou
therapi
lung
transplant
particular
pretranspl
screen
highli
resist
bacteri
fungal
airway
colon
may
consid
help
guid
peritransplant
antimicrobi
prophylaxi
posttranspl
period
risk
particular
infect
vari
depend
time
sinc
transplant
surgeri
fig
exampl
risk
surgic
complic
nosocomi
infect
highest
first
day
wherea
risk
reactiv
latent
opportunist
infect
highest
earli
net
state
immunosuppress
peak
declin
reduct
immunosuppress
mainten
level
similarli
risk
communityacquir
infect
increas
exposur
transplant
recipi
outpati
set
keep
timelin
mind
well
remain
cogniz
individu
patient
pretranspl
risk
factor
exposur
aid
clinician
formul
focus
differenti
diagnosi
infecti
complic
aris
recipi
cmv
remain
signific
problem
lung
transplant
despit
advanc
viral
diagnost
prophylaxi
treatment
strategi
recent
prospect
multicent
cohort
studi
resistra
group
show
despit
month
cmvdirect
viral
prophylaxi
postlung
transplant
pneumonia
report
caus
cmv
lung
transplant
recipi
highest
risk
develop
cmv
diseas
among
sot
recipi
although
risk
cmv
decreas
time
situat
like
combin
larg
cmv
viral
load
transmit
via
cmvposit
lung
allograft
rel
type
allograft
intens
immunosuppress
often
requir
lung
transplant
recipi
well
common
risk
factor
share
organ
recipi
risk
factor
includ
serostatu
donor
recipi
seroneg
recipi
seroposit
organ
highest
risk
presenc
allograft
reject
use
induct
immunosuppress
presenc
concurr
infect
primarili
virus
area
recent
investig
includ
defect
cmvspecif
cellmedi
immun
cmi
polymorph
variou
compon
innat
immun
system
host
factor
renal
dysfunct
definit
cmv
infect
diseas
develop
use
clinic
research
set
cmv
infect
requir
evid
cmv
viral
replic
via
accept
form
laboratori
test
see
later
discuss
wherea
cmv
diseas
requir
evid
cmv
viral
replic
plu
attribut
symptom
includ
fever
malais
leukopenia
thrombocytopenia
evid
tissueinvas
diseas
pneumon
coliti
hepat
retin
recent
interest
also
focus
indirect
effect
cmv
includ
immunomodulatori
effect
viru
increas
risk
develop
opportunist
infect
human
herpesviru
ebv
fungal
bacteri
ebvrel
posttranspl
lymphoprolif
diseas
increas
risk
acut
chronic
reject
allograft
contribut
cmv
develop
bronchiol
obliteran
syndrom
bo
still
investig
conflict
result
report
recent
systemat
review
sever
singlecent
public
recent
singlecent
studi
snyder
colleagu
report
posttranspl
incid
cmv
pneumon
found
increas
risk
subsequ
bo
univari
multivari
analys
hazard
ratio
depend
time
depend
signific
advanc
cmvspecif
diagnost
test
recent
mani
case
cmv
infect
diseas
initi
diagnos
base
detect
viremia
last
decad
quantit
nucleic
acid
test
primarili
via
polymeras
chain
reaction
pcr
becom
wide
accept
method
cmv
viral
load
monitor
previou
modal
cmv
antigenemia
detect
via
antigen
detect
peripher
white
blood
cell
fallen
favor
rel
insensit
labor
intens
howev
lack
standard
cmv
nucleic
acid
test
platform
procedur
across
mani
laboratori
produc
signific
interlaboratori
variabl
situat
make
interpret
viral
load
result
obtain
differ
laboratori
problemat
also
pose
problem
establish
uniform
viral
load
cutoff
posit
neg
result
one
promis
area
cmv
diagnost
measur
cmvspecif
cmi
predictor
develop
cmv
viremia
diseas
complet
primari
prophylaxi
recent
studi
kumar
colleagu
use
commerci
avail
cmvspecif
interferon
g
releas
assay
quantiferoncmv
cellesti
valencia
ca
usa
test
serial
cmvspecif
cmi
sot
recipi
posttranspl
cmv
prophylaxi
period
postprophylaxi
cmv
diseas
within
first
month
transplant
occur
patient
detect
cmvspecif
cmi
versu
patient
posit
quantiferoncmv
result
suggest
possibl
role
predict
lateonset
cmv
diseas
cmvspecif
enzymelink
immunosorb
spot
assay
intracellular
cytokin
stain
follow
flow
cytometri
also
studi
predictor
cmv
viremia
diseas
assay
standard
may
readili
avail
transplant
center
current
recommend
routin
patient
monitor
cochran
databas
review
antivir
medic
prevent
cmv
diseas
sot
recipi
show
cmv
prophylaxi
reduc
risk
cmv
infect
diseas
allcaus
mortal
heterogen
group
sot
recipi
consensu
guidelin
cmv
prophylaxi
recent
updat
european
north
american
transplant
societi
screen
potenti
lung
allograft
donor
recipi
cmv
igg
test
perform
allow
risk
stratif
implement
appropri
prophylaxi
strategi
gener
accept
strategi
cmv
prophylaxi
solidorgan
transplant
univers
prophylaxi
administr
antivir
atrisk
individu
preemptiv
therapi
administr
antivir
individu
demonstr
viral
replic
strategi
compar
random
fashion
lung
transplant
specif
current
expert
opinion
societi
favor
use
univers
prophylaxi
highrisk
patient
includ
lung
transplant
recipi
initi
univers
prophylaxi
strategi
use
intraven
ganciclovir
develop
oral
prodrug
valganciclovir
center
switch
oral
valganciclovir
exclus
oral
valganciclovir
short
cours
intraven
ganciclovir
immedi
transplant
similar
efficaci
shown
medic
center
add
cmv
hyperimmun
globulin
univers
prophylaxi
regimen
evalu
random
fashion
signific
uncertainti
remain
regard
appropri
durat
prophylaxi
recent
trial
suggest
extend
prophylaxi
year
longer
transplant
may
reduc
cmvrelat
complic
trial
signific
limit
recent
first
prospect
random
placebocontrol
trial
compar
shortcours
month
longcours
month
prophylaxi
valganciclovir
atrisk
lung
transplant
recipi
posit
donor
recipi
serolog
statu
report
palmer
colleagu
complet
initi
cours
valganciclovir
patient
random
either
placebo
short
cours
continu
prophylaxi
long
cours
subsequ
follow
develop
cmv
diseas
month
transplant
investig
found
longcours
prophylaxi
patient
develop
cmv
diseas
trial
versu
shortcours
patient
signific
differ
found
cmv
resist
advers
event
acut
reject
episod
group
observ
period
subset
studi
patient
follow
develop
cmv
diseas
beyond
first
month
transplant
howev
late
cmv
diseas
rate
low
group
longcours
shortcours
subject
suggest
longer
durat
prophylaxi
may
simpli
delay
onset
cmv
diseas
may
also
reduc
overal
incid
whether
addit
studi
examin
vari
durat
prophylaxi
month
involv
longerterm
cmv
surveil
prophylaxi
confirm
find
unknown
reiniti
cmv
prophylaxi
consid
treatment
acut
reject
antilymphocyt
antibodi
therapi
highdos
steroid
use
although
preemptiv
approach
may
result
reduc
drug
cost
avoid
drugrel
toxic
promot
cmvspecif
cmi
via
exposur
lowlevel
viral
replic
center
favor
univers
prophylact
strategi
consensu
guidelin
preemptiv
approach
requir
frequent
blood
work
rapid
access
reaction
result
also
concern
whether
weekli
test
might
miss
onset
period
rapid
viral
replic
thu
risk
develop
sever
cmv
diseas
treatment
initi
especi
higherrisk
lung
transplant
recipi
gener
also
unknown
whether
lowlevel
cmv
viral
replic
may
facilit
increas
indirect
effect
viru
includ
reject
limit
data
regard
use
preemptiv
prophylaxi
lung
transplant
set
specif
larg
random
trial
avail
studi
rais
concern
earlier
onset
cmv
diseas
higher
rate
ganciclovir
resist
patient
receiv
preemptiv
therapi
highlight
need
research
area
treatment
cmv
diseas
requir
coordin
reduct
mainten
immunosuppress
conjunct
antivir
medic
discuss
recent
consensu
guidelin
cmv
tissueinvas
diseas
intraven
ganciclovir
mgkg
everi
hour
adjust
renal
function
prefer
treatment
recent
studi
shown
isol
cmv
viremia
cmv
syndrom
mild
moder
cmv
diseas
oral
valganciclovir
mg
everi
hour
adjust
renal
function
noninferior
intraven
ganciclovir
mix
popul
sot
recipi
howev
caution
exercis
patient
adequ
absorpt
oral
medic
question
eg
cmv
gastrointestin
diseas
patient
may
compliant
oral
therapi
treatment
continu
minimum
week
cessat
viral
replic
verifi
cmvattribut
symptom
resolv
quantit
nucleic
acid
test
antigenemia
test
perform
weekli
basi
treatment
follow
virolog
respons
therapi
confirm
resolut
viremia
consecut
neg
test
least
day
apart
recommend
complet
therapi
secondari
prophylaxi
lowerdos
valganciclovir
mg
daili
adjust
renal
function
consid
highrisk
patient
complet
cmv
treatment
especi
reduct
immunosuppress
possibl
addit
cmv
hyperimmun
globulin
sever
cmv
diseas
pneumon
may
consid
patient
fail
respond
standard
antivir
therapi
suspect
ganciclovirresist
cmv
diseas
evalu
genotyp
resist
test
mutat
viral
gene
product
addit
therapi
toxic
antivir
agent
foscarnet
cidofovir
may
requir
case
infecti
diseas
consult
consid
patient
suspect
document
cmv
resist
communityacquir
respiratori
virus
carv
common
among
lung
transplant
recipi
especi
ambulatori
set
recent
prospect
studi
detect
viral
pathogen
bronchoalveolar
lavag
bal
lung
transplant
recipi
enrol
studi
period
virus
caus
sever
lower
respiratori
tract
infect
patient
result
signific
morbid
mortal
sever
studi
also
suggest
carv
infect
independ
risk
factor
acut
chronic
reject
popul
although
remain
controversi
group
virus
includ
notabl
pathogen
influenza
b
novel
respiratori
syncyti
viru
rsv
adenoviru
parainfluenza
coronavirus
sever
acut
respiratori
syndrom
viru
well
rhinoviru
enterovirus
human
metapneumoviru
bocaviru
polyomavirus
ki
wu
virus
diagnosi
respiratori
virus
aid
develop
pcrbase
quantit
nucleic
acid
test
known
clinic
relev
virus
consider
centertocent
variabl
particular
panel
virus
routin
test
clinician
awar
virus
circul
commun
ensur
adequ
test
perform
rapid
antigen
test
avail
limit
number
carv
sensit
immunocompromis
patient
unclear
thu
neg
test
definit
exclud
viral
infect
direct
fluoresc
antibodi
test
also
avail
carv
appropri
sampl
viral
diagnost
includ
nasopharyng
swab
aspir
wash
bal
specimen
howev
assay
sensit
may
vari
sampl
collect
effect
antivir
therapi
carv
avail
notabl
except
influenza
viru
perhap
rsv
thu
appropri
infect
control
strategi
includ
hand
hygien
droplet
precaut
mandatori
prevent
spread
diseas
find
especi
import
health
care
set
transplant
patient
seem
prolong
viral
shed
infect
support
care
reduct
immunosuppress
possibl
remain
mainstay
carv
treatment
consensu
guidelin
manag
common
carv
novel
influenza
recent
publish
current
recommend
influenza
rsv
briefli
summar
next
section
influenza
transplant
recipi
household
contact
receiv
yearli
influenza
vaccin
inactiv
influenza
vaccin
prevent
diseas
suspect
case
influenza
treat
ideal
within
hour
symptom
onset
transplant
patient
particular
may
still
receiv
benefit
therapi
initi
outsid
window
symptomat
patient
treat
regardless
durat
symptom
everi
effort
made
establish
diagnosi
influenza
includ
type
specif
therapi
depend
resist
pattern
current
circul
virus
case
neuraminidas
inhibitor
oseltamivir
zanamivir
taken
twice
daili
adjust
renal
function
recommend
either
influenza
b
altern
inhibitor
ie
amantidin
rimantidin
could
consid
influenza
strain
treatment
continu
least
day
may
benefit
extend
therapi
beyond
period
patient
slow
clinic
respond
evid
continu
viral
shed
repeat
test
unvaccin
patient
suspect
exposur
individu
influenza
receiv
prophylaxi
oseltamivir
zanamivir
given
daili
adjust
renal
function
day
last
known
exposur
contact
season
extend
prophylaxi
recommend
concern
emerg
viral
resist
although
rsv
primarili
consid
signific
pathogen
young
children
lung
transplant
recipi
risk
develop
sever
lower
respiratori
tract
infect
rsv
vaccin
licens
prevent
rsv
antivir
treatment
strategi
controversi
support
care
reduct
immunosuppress
possibl
univers
recommend
use
ribavirin
transplant
recipi
remain
controversi
lack
control
studi
popul
aerosol
ribavirin
commonli
use
pediatr
popul
season
rsv
bronchiol
limit
data
suggest
benefit
lower
tract
diseas
stem
cell
transplant
popul
addit
highdos
steroid
adjunct
antibodybas
therapi
palivizumab
rsv
immunoglobulin
ig
intraven
immunoglobulin
controversi
two
small
case
seri
suggest
role
parenter
oral
ribavirin
lung
transplant
patient
specif
studi
treat
patient
ribavirin
oral
formul
intraven
plu
highdos
oral
parenter
corticosteroid
repeat
nasopharyng
swab
neg
median
followup
greater
day
studi
subject
full
recoveri
fev
forc
expiratori
volum
second
resolut
case
late
bo
identifi
total
subject
oral
ribavirin
studi
report
advers
event
intraven
studi
report
mild
revers
hemolyt
anemia
random
studi
need
fulli
assess
use
ribavirin
popul
consensu
recommend
prophylaxi
palivizumab
rsv
ig
transplant
recipi
bacteri
pathogen
remain
common
caus
pneumonia
lung
transplant
gramneg
bacteria
respons
bulk
diseas
pseudomona
aeruginosa
commonli
isol
speci
gramneg
acinetobact
spp
enterobacteriacea
stenotrophomona
spp
burkholderia
spp
also
frequent
caus
posttranspl
pneumonia
colon
airway
transplant
especi
patient
cystic
fibrosi
cf
import
consider
determin
suitabl
transplant
postop
care
posttranspl
colon
may
import
factor
develop
bo
colon
resist
gramneg
bacteria
transplant
seem
affect
surviv
transplant
notabl
except
certain
burkholderia
speci
recommend
resist
pattern
known
pretranspl
colon
bacteria
taken
account
peritranspl
antimicrobi
prophylaxi
use
histor
patient
cf
colon
b
cepacia
transplant
poorer
outcom
colon
lead
exclus
patient
consider
transplant
howev
recent
studi
reveal
genet
distinct
speci
genomovar
make
b
cepacia
complex
bcc
b
cenocepacia
genomovar
iii
b
multivoran
genomovar
ii
caus
bulk
diseas
patient
cf
find
allow
precis
studi
specif
bcc
genomovar
context
lung
transplant
sever
recent
studi
suggest
infect
b
cenocepacia
specif
risk
factor
poor
outcom
transplant
studi
found
increas
risk
death
among
patient
infect
b
cenocepacia
wherea
infect
noncenocepacia
speci
significantli
wors
outcom
uninfect
control
addit
studi
murray
colleagu
subset
patient
infect
nonepidem
strain
b
cenocepacia
higher
risk
death
compar
transmiss
epidem
strain
significantli
differ
uninfect
patient
investig
data
also
suggest
infect
b
gladioli
transplant
associ
increas
risk
death
taken
togeth
new
data
suggest
specif
select
criteria
might
establish
base
specif
bcc
genomovar
isol
ie
b
cenocepacia
vs
b
multivoran
presenc
nonepidem
versu
epidem
strain
b
cenocepacia
presenc
b
gladioli
strategi
may
allow
access
transplant
patient
cf
bcc
lowerstandard
risk
posttranspl
complic
relev
posit
donor
bacteri
cultur
address
sever
recent
studi
histor
presenc
purul
secret
numer
white
blood
cell
bacteria
sputum
gram
stain
preclud
consider
donor
lung
transplant
singlecent
retrospect
studi
avlon
colleagu
suggest
longer
stay
intens
care
unit
longer
durat
mechan
ventil
poorer
surviv
recipi
receiv
donor
lung
posit
gram
stain
howev
sever
recent
studi
suggest
posit
donor
gram
stain
lead
poorer
posttranspl
outcom
target
aggress
antimicrobi
prophylaxi
given
initi
weill
colleagu
report
differ
incid
posttranspl
pneumonia
day
durat
mechan
ventil
recipi
donor
lung
posit
neg
gram
stain
patient
treat
standard
postop
antibiot
prophylaxi
vancomycin
plu
thirdgener
cephalosporin
day
current
suggest
lung
donor
accept
criteria
state
posit
gram
stain
donor
tracheal
aspir
preclud
lung
donat
amount
purul
secret
probabl
unproven
import
associ
posttransplant
bacteri
colon
risk
develop
bo
becom
clear
recent
year
sever
studi
suggest
posttransplant
colon
gramneg
rod
gnr
particularli
pseudomona
aeruginosa
associ
reduc
bosfre
surviv
vo
colleagu
describ
retrospect
studi
lung
transplant
recipi
colon
gnr
associ
lower
bosfre
surviv
univari
analysi
trend
toward
statist
signific
multivari
analysi
gottlieb
colleagu
examin
prospect
cohort
patient
cf
colon
gnr
transplant
subject
follow
median
day
subject
remain
chronic
colon
gnr
lower
rate
bosfre
surviv
botha
colleagu
report
de
novo
colon
p
aeruginosa
transplant
associ
higher
incid
bo
shorter
period
bosfre
surviv
gnr
colon
airway
lead
bo
still
unclear
report
vo
colleagu
associ
lung
transplant
recipi
p
aeruginosa
colon
presenc
bile
acid
bal
sampl
suggest
aspir
may
underli
mechan
incid
nontubercul
mycobacteri
ntm
infect
sot
larg
unknown
sever
recent
report
suggest
may
underrecogn
caus
posttranspl
complic
two
singlecent
case
seri
late
found
patient
patient
lung
transplant
patient
respect
ntm
infect
period
late
howev
recent
studi
suggest
increas
incid
ntm
infect
particularli
mycobacterium
abscessu
patient
cf
may
particular
risk
colon
infect
organ
factor
strongli
link
invas
infect
cf
pretranspl
colon
nontubercul
mycobacteria
isol
abscessu
particular
abscessu
seem
emerg
pathogen
special
interest
lung
transplant
multipl
case
report
small
case
seri
suggest
abscessu
may
result
wors
outcom
transplant
sever
patient
experienc
dissemin
diseas
death
result
abscessu
infect
although
intern
survey
lung
transplant
center
conduct
found
overal
low
incid
abscessu
infect
affect
patient
pleuropulmonari
infect
requir
treatment
die
result
infect
recent
review
sever
meet
abstract
focus
increas
recognit
abscessu
sot
recipi
includ
lung
recipi
note
increas
risk
dissemin
mortal
effect
ntm
infect
variabl
regard
lung
transplant
outcom
although
avium
complex
long
recogn
colon
caus
pulmonari
infect
patient
underli
lung
diseas
includ
chronic
obstruct
pulmonari
diseas
effect
lung
transplant
less
notabl
similarli
ntm
infect
report
lung
transplant
candid
recipi
organ
commonli
describ
notabl
caus
excess
morbid
mortal
seen
abscessu
candid
lung
transplant
screen
ntm
infect
respiratori
cultur
radiograph
clinic
find
suggest
consid
treatment
transplant
possibl
diagnosi
treatment
ntm
infect
summar
recent
guidelin
american
thorac
societi
infecti
diseas
societi
america
idsa
criteria
applic
transplant
recipi
reflect
current
ast
infecti
diseas
guidelin
suscept
test
perform
clinic
relev
isol
evolv
resist
pattern
mani
ntm
isol
eg
abscessu
potenti
drug
interact
issu
eg
use
rifamycin
avium
diseas
addit
repeat
suscept
test
perform
diseas
recur
treatment
induc
mechan
drug
resist
isol
lung
transplant
recipi
except
high
risk
fungal
infect
recent
estim
place
incid
fungal
infect
overal
mortal
infect
caus
candida
aspergillu
speci
lung
transplant
recipi
may
also
infect
zygomycet
scedosporium
fusarium
cryptococcu
speci
endem
mycos
histoplasmosi
coccidiodomycosi
pneumocysti
jirovecii
uncommon
univers
prophylaxi
commonli
trimethoprimsulfamethoxazol
standard
care
lung
transplant
recipi
seem
case
cryptococcosi
endem
mycos
caus
reactiv
latent
diseas
care
pretranspl
evalu
critic
determin
histori
diseas
transplant
situat
previou
recent
diseas
caus
endem
mycos
may
warrant
specif
antifung
prophylaxi
current
recommend
sot
recipi
recent
publish
aspergillu
aspergillu
infect
manifest
varieti
way
cours
lung
transplant
includ
pretranspl
airway
colon
posttranspl
tracheobronch
invas
pulmonari
aspergillosi
dissemin
diseas
work
definit
entiti
previous
publish
incid
complic
vari
depend
literatur
cite
recent
literatur
review
found
airway
colon
aspergillu
without
diseas
commonli
seen
patient
minor
patient
less
develop
either
tracheobronch
invas
aspergillosi
ia
two
recent
fungal
surveil
network
path
allianc
registri
transnet
transplantassoci
infect
surveil
network
note
aspergillu
account
fungal
infect
sot
patient
candida
second
common
fungu
seen
approxim
seri
data
regard
role
pretransplant
aspergillu
colon
develop
posttranspl
fungal
complic
limit
helmi
colleagu
perform
retrospect
singlecent
studi
compar
colon
patient
cf
transplant
recipi
cf
patient
cf
like
colon
aspergillu
tracheobronchi
infect
transplant
nevertheless
ia
dissemin
infect
occur
patient
cf
uncommon
recipi
cf
addit
literatur
review
compris
studi
found
case
transplant
recipi
cf
colon
aspergillu
transplant
progress
ia
recent
singlecent
retrospect
analysi
mold
infect
explant
lung
report
explant
invas
fungal
infect
pretranspl
diagnosi
infect
occur
less
time
associ
unrecogn
pretranspl
mold
infect
invas
fungal
infect
transplant
regardless
voriconazol
prophylaxi
attribut
mortal
patient
earlier
studi
suggest
posttranspl
aspergillu
colon
associ
higher
risk
develop
ia
subsequ
singlecent
seri
combin
pool
data
analysi
publish
literatur
mehrad
colleagu
suggest
risk
may
substanti
lower
colon
subject
progress
ia
singlecent
seri
patient
pool
literatur
review
progress
ia
gold
standard
diagnosi
ia
remain
biopsi
cultur
accompani
compat
clinic
radiograph
abnorm
howev
develop
rapid
minim
invas
diagnost
test
modal
aspergillosi
remain
area
urgent
clinic
need
galactomannan
polysaccharid
cell
wall
compon
aspergillu
antigen
detect
bodi
fluid
perform
use
enzym
immunoassay
techniqu
platelia
galactomannan
eia
biorad
laboratori
hercul
ca
usa
galactomannan
assay
studi
primarili
hematopoiet
stem
cell
transplant
popul
current
approv
use
twiceweekli
serumbas
screen
test
develop
ia
sever
studi
assess
use
diagnosi
ia
infect
lung
transplant
recipi
mix
result
prospect
test
serum
specimen
poor
sensit
ia
detect
case
aspergillu
tracheobronch
test
bal
promis
sensit
rang
specif
studi
falseposit
test
result
seen
use
blactam
antibiot
especi
piperacillintazobactam
ticarcillinclavulan
amoxicillin
test
may
crossreact
presenc
mold
endem
fungi
bdglucan
assay
test
cell
wall
compon
present
fungi
thu
specif
aspergillosi
test
also
high
falseposit
rate
critic
ill
patient
seem
better
sensit
galactomannan
test
pcrbase
method
detect
aspergillu
develop
yet
standard
clinic
use
prophylaxi
fungal
infect
lung
transplant
recipi
wide
variabl
center
center
largescal
multicent
studi
guid
prophylact
choic
guidelin
suggest
stratifi
patient
base
individu
risk
factor
includ
pretranspl
colon
aspergillu
acquir
colon
organ
first
month
transplant
theoriz
risk
factor
includ
earli
airway
ischemia
placement
bronchial
stent
singl
lung
transplant
hypogammaglobulinemia
cmv
infect
use
alemtuzumab
thymoglobulin
induct
therapi
acut
reject
requir
augment
immunosuppress
inhal
amphotericin
compound
oral
itraconazol
voriconazol
prophylaxi
strategi
use
random
control
trial
assess
approach
summari
recent
studi
result
see
ref
recent
singlecent
retrospect
sequenti
studi
compar
univers
voriconazol
prophylaxi
minimum
month
month
target
prophylaxi
itraconazol
plu
minu
inhal
amphotericin
patient
pretranspl
posttranspl
aspergillu
colon
report
reduc
ia
voriconazol
arm
howev
sever
recent
studi
report
unanticip
advers
event
lung
transplant
patient
given
prolong
voriconazol
therapi
prophylaxi
treatment
ia
includ
disabl
neuromuscular
disord
periost
resembl
hypertroph
osteoarthropathi
numer
drug
interact
azol
antifung
calcineurin
inhibitor
mtor
mammalian
target
rapamycin
inhibitor
close
attent
dose
immunosuppress
agent
imper
treatment
recommend
aspergillu
tracheobronch
recent
summar
guidelin
voriconazol
recommend
firstlin
therapi
biopsyconfirm
aspergillu
tracheobronch
along
reduct
immunosuppress
attent
paid
drug
interact
calcineurin
inhibitor
potenti
side
effect
includ
hepatotox
visual
hallucin
durat
treatment
typic
guid
bronchoscop
surveil
resolut
parenter
lipid
formul
amphotericin
b
deoxychol
remain
altern
patient
toler
voriconazol
limit
experi
use
echinocandin
ie
caspofungin
posaconazol
set
inhal
amphotericin
b
deoxychol
lipid
formul
amphotericin
use
aspergillu
tracheobronch
strategi
remain
investig
standard
approach
rigor
studi
singl
case
report
describ
weekli
topic
instil
liposom
amphotericin
b
via
bronchoscopi
combin
standard
antifung
therapi
also
recent
describ
treatment
ia
also
reli
voriconazol
firstlin
agent
consider
parenter
lipid
formul
amphotericin
b
deoxychol
echinocandin
posaconazol
itraconazol
altern
reduct
immunosuppress
import
compon
treatment
combin
therapi
agent
routin
recommend
initi
therapeut
approach
lack
evid
improv
outcom
recent
guidelin
also
suggest
monitor
voriconazol
level
serum
concentr
highli
variabl
among
patient
popul
especi
patient
cf
trough
level
mgml
recommend
optim
efficaci
prevent
toxic
surgic
intervent
includ
debrid
resect
may
necessari
lifethreaten
hemoptysi
lesion
close
proxim
great
vessel
pericardium
sinonas
infect
intracrani
lesion
surgic
assess
also
warrant
case
progress
refractori
diseas
optim
antifung
therapi
fail
durat
treatment
typic
guid
clinic
radiograph
resolut
attribut
abnorm
week
recommend
minimum
cours
therapi
role
immunomodulatori
agent
interferon
g
remain
investig
anecdot
evid
renal
transplant
recipi
support
use
approach
need
studi
valid
control
manner
incorpor
clinic
practic
note
earlier
candida
second
common
caus
invas
fungal
infect
lung
transplant
recipi
risk
factor
candid
infect
lung
transplant
recipi
often
relat
postop
complic
includ
prolong
stay
intens
care
unit
prolong
indwel
cathet
broadspectrum
antibiot
therapi
parenter
nutrit
well
heavi
growth
candida
donor
lung
manifest
candid
diseas
typic
occur
first
day
transplant
includ
bloodstream
infect
empyema
mediastin
bronchial
anastomot
breakdown
infect
vascular
anastomos
mycot
aneurysm
format
case
invas
pulmonari
candidiasi
report
adult
lung
transplant
literatur
although
pediatr
transplant
seri
proven
pulmonari
invas
fungal
infect
caus
candida
speci
despit
rel
good
antifung
therapi
target
candida
speci
prognosi
patient
invas
candid
diseas
exclud
bronchial
anastomot
diseas
grim
mortal
greater
clinic
suspicion
invas
fungal
diseas
addit
appropri
posit
cultur
criteria
use
begin
antifung
therapi
cultur
remain
gold
standard
diagnosi
candid
infect
modal
bdglucan
detect
candida
mannan
antigenemia
test
yet
suffici
sensit
specif
use
clinic
set
addit
identif
speci
level
clinic
signific
candida
isol
critic
regard
sever
speci
intrins
resist
certain
antifung
c
krusei
resist
fluconazol
wherea
isol
may
dosedepend
suscept
c
glabrata
fluconazol
c
lusitania
amphotericin
realtim
pcr
techniqu
develop
may
aid
rapid
determin
specif
candida
speci
clinic
specimen
assay
current
experiment
suggest
treatment
invas
candid
infect
summar
recent
ast
guidelin
idsa
guidelin
cultur
data
essenti
case
determin
identif
isol
subsequ
suscept
inform
nonneutropen
patient
mild
moder
ill
previou
signific
azol
exposur
low
risk
c
glabrata
infect
highdos
fluconazol
may
use
initi
howev
given
increas
use
azol
prophylaxi
fluconazol
voriconazol
lung
transplant
patient
higher
risk
level
develop
sever
ill
mani
expert
recommend
empir
therapi
echinocandin
liposom
amphotericin
b
depend
renal
toler
ongo
treatment
adjust
base
suscept
data
durat
treatment
depend
extent
sever
diseas
rang
minimum
week
neg
blood
cultur
uncompl
candidemia
prolong
cours
treatment
potenti
lifelong
suppress
endocard
similar
condit
treatment
candida
speci
isol
recipi
airway
secret
less
straightforward
candida
spp
common
colon
oropharynx
incid
invas
candid
diseas
lung
transplant
recipi
colon
candida
spp
seem
rare
mani
center
routin
use
posttranspl
antifung
prophylaxi
agent
use
durat
therapi
highli
variabl
note
earlier
howev
expert
agre
antifung
prophylaxi
use
agent
target
candida
aspergillu
speci
case
candida
tracheobronch
visual
inspect
anastomosi
perform
cultur
histolog
confirm
critic
cultur
obtain
set
aspergillu
anoth
common
caus
necrot
anastomot
infect
choic
antifung
therapi
may
differ
commonli
use
candid
infect
choic
therapi
guid
cultur
result
discuss
earlier
durat
therapi
guid
bronchoscop
confirm
resolut
infect
infect
continu
major
sourc
morbid
mortal
lung
transplant
recipi
care
pretranspl
assess
select
appropri
prophylact
regimen
prompt
diagnosi
treatment
posttranspl
infect
may
improv
posttranspl
outcom
nevertheless
uniqu
exposur
transplant
organ
extern
environ
intens
immunosuppress
requir
prevent
reject
continu
provid
uniqu
challeng
manag
infect
lung
transplant
